Hơn 300 chữ ký kêu gọi Gilead mở rộng sản xuất thuốc lenacapavir điều trị HIV

Trong thư gửi Gilead, hơn 300 người có tầm ảnh hưởng cho rằng nếu tất cả những người sống chung với AIDS được tiếp cận lenacapavir thì mối đe dọa sức khỏe toàn cầu này có thể kết thúc vào năm 2030.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Bộ Y tế: Thu hồi toàn quốc 162 sản phẩm mỹ phẩm vi phạm của Mailisa

Bộ Y tế: Thu hồi toàn quốc 162 sản phẩm mỹ phẩm vi phạm của Mailisa

Thuốc - Dinh dưỡng
Cục Quản lý Dược (Bộ Y tế) vừa ban hành quyết định thu hồi số tiếp nhận Phiếu công bố, đồng thời đình chỉ lưu hành, thu hồi toàn quốc hơn 160 sản phẩm mỹ phẩm vi phạm của Công ty Trách nhiệm hữu hạn Sản xuất Thương mại Dịch vụ Xuất nhập khẩu MK Skincare còn hạn sử dụng (đây...
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh